VSV-hIFNbeta

AXP000136.1 · Oncolytic virus

Platform
vesicular stomatitis virus (Indiana serotype, human IFN-beta-armed)
Originator
Mayo Clinic
Sponsor
Mayo Clinic

Names

NameTypeSource
VSV-hIFNbetapreferred name, codecurator, ncit
Recombinant Vesicular Stomatitis Virus-expressing Interferon-betasynonymncit
VSV-hIFN-bsynonymncit
VSV-IFN-beta ambiguoussynonymncit

Virus

Role
Oncolytic
Family
Rhabdoviridae
Virus
vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
Strain
Indiana, recombinant
Replication
replicating
Modifications
human interferon beta cassette inserted; no NIS cassette
Transgenes
IFNB1
Route
intratumoral, intra arterial
Source
evidence

Cross-references

NCI Thesaurus
C102545

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07510334VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingPhase 22026-04-212033-08-0118Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingPhase 12024-01-052028-12-3121Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Peripheral T Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Relapsed Anaplastic Large Cell Lymphoma; Relapsed Mycosis Fungoides; Relapsed Peripheral T-Cell Lymphoma
NCT03865212Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV MelanomaTerminatedPhase 12019-06-122025-10-1212Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Choroid Melanoma; Metastatic Melanoma; Metastatic Mucosal Melanoma; Metastatic Uveal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma
NCT03120624VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerActive not recruitingPhase 12017-09-152023-08-2934Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinosarcoma; Stage IV Uterine Corpus Cancer AJCC v7
NCT03017820A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingPhase 12017-04-042028-12-3199B-Cell Non-Hodgkin Lymphoma; Histiocytic and Dendritic Cell Neoplasm; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Plasma Cell Myeloma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Acute Myeloid Leukemia; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Plasma Cell Myeloma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma
NCT01628640Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid TumorsCompletedPhase 12012-08-032019-04-1917Advanced Malignant Solid Neoplasm; Hepatocellular Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 36052732Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.Hepatology (Baltimore, Md.)2023cited by trial NCT01628640
PMID 36898933Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?Blood reviews2023cited by trial NCT03017820
PMID 35175355Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.Blood advances2022cited by trial NCT03017820

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 19911974Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.Human gene therapy2010name in abstract: VSV-hIFNbeta
PMID 12885903Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.Journal of virology2003name in abstract: VSV-hIFNbeta

NIH grants

ProjectTitleOrganisationPIYearsLinked by
DP2CA195764Oncolytic Virotherapy in Hepatocellular CancerMAYO CLINIC ARIZONABORAD, MITESH2014–2016name in abstract: VSV-hIFN-b
R01FD004781Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular CarcinomaMAYO CLINIC ARIZONABORAD, MITESH2014–2016name in title: VSV-hIFN-b

Notes

Recombinant VSV expressing human interferon beta WITHOUT the sodium iodide symporter, i.e. the construct preceding VSV-IFNbeta-NIS (AXP000119). NCIt keeps the two apart (C102545 vs C131580). Dosed intratumorally and intrahepatically in the completed Mayo phase 1 NCT01628640 (2012-2019) in hepatocellular carcinoma and other solid tumours.

How to cite

VSV-hIFNbeta (AXP000136.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000136.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.